Abatacept (Genetical Recombination) Subcutaneous Injection 125mg/1mL (Orencia® / オレンシア皮下注125mgシリンジ1mL)

JPY ¥28,800

Japanese T-cell Selective Costimulation Modulator (Abatacept (Genetical Recombination) 125mg/1mL). Subcutaneous injection for rheumatoid arthritis with inadequate response to existing therapies. 1 syringe. Mfd. by Bristol-Myers Squibb K.K., Japan.

Bulk deal
Quantity Discount Discounted price
5 - 9 8% JPY ¥26,496
10 - 19 12% JPY ¥25,344
20 + 18% JPY ¥23,616
SKU: ORC-125-INJ Category:

Description

Product Overview / 商品概要

Orencia Subcutaneous Injection 125mg Syringe 1mL (オレンシア皮下注125mgシリンジ1mL)
Generic: Abatacept (Genetical Recombination) / アバタセプト(遺伝子組換え)
Therapeutic Category: T-cell Selective Costimulation Modulator, Abatacept (Genetical Recombination) Preparation / T細胞選択的共刺激調節剤 アバタセプト(遺伝子組換え)製剤
Manufactured by: Bristol-Myers Squibb K.K. / ブリストル・マイヤーズ スクイブ株式会社

Composition & Specification / 組成・規格

Active Ingredient: Abatacept (Genetical Recombination) 125mg per 1mL syringe / シリンジ1mL中 アバタセプト(遺伝子組換え)125mg
Additives: Refined sucrose 170mg, Polyoxyethylene (160) polyoxypropylene (30) glycol 8mg, Sodium dihydrogen phosphate monohydrate 0.286mg, Anhydrous disodium hydrogen phosphate 0.838mg / 精製白糖 170mg、ポリオキシエチレン(160)ポリオキシプロピレン(30)グリコール 8mg、リン酸二水素ナトリウム一水和物 0.286mg、無水リン酸一水素ナトリウム 0.838mg
Appearance: Colorless to slightly yellowish clear or slightly opalescent liquid; pH 6.8–7.4; osmotic pressure ratio (relative to physiological saline) approximately 3
外観: 無色〜微黄色の澄明又はわずかに乳白光を呈する液、pH 6.8〜7.4、浸透圧比(生理食塩液に対する比)約3

Indications / 効能効果

EN: Rheumatoid arthritis with an inadequate response to existing therapies (including prevention of structural joint damage)
JA: 既存治療で効果不十分な関節リウマチ(関節の構造的損傷の防止を含む)

Dosage and Administration / 用法用量

EN: In adults, administer a loading dose by intravenous infusion of abatacept (genetical recombination) for intravenous infusion on Day 1, followed by a subcutaneous injection of 125mg of this product on the same day, then 125mg subcutaneously once weekly thereafter. Alternatively, treatment may be initiated with 125mg subcutaneously once weekly without a loading dose.
JA: 通常、成人には、投与初日に負荷投与としてアバタセプト(遺伝子組換え)点滴静注用製剤の点滴静注を行った後、同日中に本剤125mgの皮下注射を行い、その後、本剤125mgを週1回、皮下注射する。また、本剤125mgの週1回皮下注射から開始することもできる。

Contraindications / 禁忌

EN: 2.1 Patients with a history of hypersensitivity to any component of this product; 2.2 Patients with serious infections
JA: 2.1 本剤の成分に対し過敏症の既往歴のある患者、2.2 重篤な感染症の患者

Regulatory Information / 規制情報

Approval No.: 22500AMX01002000
Sales Started: August 2013 / 2013年8月
Classification Code: 873999
Storage: Store at 2–8°C; do not freeze / 凍結を避け、2〜8℃で保存
Shelf Life: 2 years / 2年

Packaging / 包装

Main Package (for sale): 1 syringe / 1シリンジ
Other Available Packages (by special order): 1 syringe

Full product insert (添付文書) is attached as a downloadable PDF. For detailed precautions, drug interactions, and safety information, please refer to the official package insert.

Additional information

重さ 0.15 kg

Reviews

There are no reviews yet.

Be the first to review “Abatacept (Genetical Recombination) Subcutaneous Injection 125mg/1mL (Orencia® / オレンシア皮下注125mgシリンジ1mL)”

メールアドレスが公開されることはありません。 ※ が付いている欄は必須項目です

Export from Japan — Abatacept (Genetical Recombination) Subcutaneous Injection 125mg

🏭 Supply & Origin

  • Country of Origin: Japan
  • Regulatory Standard: PMDA (Japan) / GMP Compliant
  • Pharmacopoeia: Japanese Pharmacopoeia (JP)
  • Supplier: Mate Co., Ltd. — Licensed Pharmaceutical Wholesaler (License No. B14309, Osaka)
  • Supply Capacity: Full-line sourcing through Japan's regulated distribution channels

🚚 Shipping & Trade Terms

  • Incoterms: FOB Kansai International Airport (KIX)
  • Shipping: Air freight via B/L or AWB
  • Payment: 100% T/T in advance
  • Lead Time: 2-4 weeks after payment confirmation
  • Available Regions: EU, LATAM, APAC, Middle East, Africa

Request a Quotation

For pricing, MOQ, and regulatory documentation, contact our export team:

Email: kurimoto@mate-osaka.co.jp
Tel: +81-72-665-5736

All exports are conducted through proper regulatory procedures including customs clearance, B/L or AWB documentation, and T/T advance payment. We do not engage in hand-carry, cash transactions, or sales to unlicensed parties.